Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Monday

Phio Pharmaceuticals (NASDAQ:PHIO) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.19. On average, analysts expect Phio Pharmaceuticals to post $-9 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Phio Pharmaceuticals Trading Up 3.4%

Shares of NASDAQ:PHIO opened at $1.22 on Monday. The stock has a market cap of $14.18 million, a PE ratio of -0.84 and a beta of 0.90. The stock’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.49. Phio Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $4.19.

Analysts Set New Price Targets

Several brokerages have recently commented on PHIO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Phio Pharmaceuticals in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Phio Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $14.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Cetera Investment Advisers grew its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 42,500 shares of the company’s stock after acquiring an additional 9,000 shares during the period. Cetera Investment Advisers owned about 0.39% of Phio Pharmaceuticals worth $45,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.